Menu
Synergy in Action

2024 Autumn Conference Posters

Click title to view pdf. Posters are in alpha order by first author. 

Abbas – Measurement of positive and negative symptoms through speech analysis from PANSS interview recordings in patients with schizophrenia (Abstract)

Alphs – Patient ratings from a genetic biomarker guided trial with liafensine support clinician-rated findings in patients with treatment resistant depression (Abstract)

Campbell – Assessing amnestic mild cognitive impairment using smartphone-based ecological momentary cognitive testing: Sensitivity of various performance metrics (Abstract)

Chaturvedi – Capturing changes in positive affect and social functioning using ecological momentary assessment (EMA) in a 12-month treatment trial in schizophrenia (Abstract)

Cole – Two for the price of one: HAM-D rating variability does not necessarily increase with the number of raters (Abstract)

Das – Artefact rejection in EEG and quality control (Abstract)

DeBonis – Development of a digital health tool evaluation framework for operational sponsor considerations in clinical trials (Abstract)

Desjardins – Comparing effectiveness of manufacturer-recommended therapeutic ADT dose as detailed in the Antidepressant Treatment Response Questionnaire (ATRQ) (Abstract)

Efstathiadis – Correcting speaker labeling errors in automated transcripts of clinical conversations (Abstract)

Geraci – Development of the Treatment Attitude Profile (TAP) scale: AI/ML-driven insights for clinical trial enrichment to minimize placebo response (Abstract)

Geraci – Insights from the CATIE schizophrenia trial: AI/ML-driven analysis to identify key variables influencing treatment outcomes (Abstract)

Harvey – Examining negative symptoms and everyday functioning as a correlated time series: Causal analysis of treatment effects in a 12-month open-label study (Abstract)

Hopkins – A clinical trial inclusion criteria to enrich for patients presenting with canonical symptom structure in bipolar depression (Abstract)

Horan – Longitudinal convergence of dispersed clinical ratings and ecological momentary assessment burst assessments of negative symptoms in schizophrenia (Abstract)

Karas – Functional unblinding evaluation of central raters in a large psychedelic clinical trial (Abstract)

Karazsia – Equipercentile linking masks data quality concerns in depression clinical trials (Abstract)

Kark – Audio and video digital measurements observed in naturalistic settings predict PANSS Marder factor scores in schizophrenia (Abstract)

Kelman – Integrating synchronous AI-based fidelity adherence monitoring of facilitators in psychedelic clinical trials (Abstract)

Keyser-Marcus – The utility of the NIDA Phenotyping Assessment Battery in a combined enrichment strategy for determining eligibility in addiction clinical trials (Abstract)

Kosik-Gonzalez – Equating CDRS-R and MADRS scale scores in adolescents with major depressive disorder with acute suicidal ideation or behavior (Abstract)

Korolev – Standardized EEG/ERP battery for measuring drug effects in CNS trials using end-to-end automated analytic pipeline (Abstract)

Kott – Impact of low-recruiting sites on data quality in early Alzheimer’s disease clinical trials (Abstract)

Kott – Raters associated with erratic ratings differ in their scoring technique (Abstract)

Li – EEG-based, machine learning biomarker to predict treatment response from SSRI antidepressant treatment and TMS treatment of MDD and TRD patients (Abstract)

Medvescek – Quantifying exposure: Novel methods to investigate exposure treatments for trauma-related nightmares (Abstract)

Miller – Central monitoring and data quality assurance: Identifying and correcting errors in category and letter fluency tests in CNS clinical trials (Abstract)

Mukhopadhyay – Prospectively specified adaptive Bayesian borrowing: Considerations, methodologies, and implementations (Abstract)

Newsome – Analytical validation of a novel quality assurance approach for COAs in Alzheimer’s disease clinical trials (Abstract)

Pendergrass – Development of a comprehensive guide for navigating information on digital biomarkers in CNS clinical trials (Abstract)

Price – Evaluating psychotherapeutic components in psychedelic-assisted therapies: A comprehensive review (Abstract)

Rundle – Insights in psychedelic research – Historical overview (Abstract)

Setton – Reference ranges of healthy brain network activity to inform CNS treatment development (Abstract)

Steele – Differences in detected error rate and resolution between clinical data validation and video review in Phase III clinical trials (Abstract)

Tomioka – Enhancing speech analysis through de-hallucination and LLM diarization in physician-patient interviews (Abstract)